Impact of a variable number tandem repeat in the CYP2C9 promoter on warfarin sensitivity and responsiveness in Jordanians with cardiovascular disease

References

• AnsellJHirshJHylekEJacobsonACrowtherMPalaretiGPharmacology and management of the vitamin K antagonistsChest20081336160S198S18574265
   PubMed Web of Science ®Google Scholar
• KaminskyLSZhangZYHuman P450 metabolism of warfarinPharmacol Ther199773167749014207
   PubMed Web of Science ®Google Scholar
• WallinRHutsonSMWarfarin and the vitamin K-dependent gamma-carboxylation systemTrends Mol Med200410729930215242675
   PubMed Web of Science ®Google Scholar
• KingCRDeychEMilliganPGamma-glutamyl carboxylase and its influence on warfarin doseThromb Haemost2010104475075420694283
   PubMed Web of Science ®Google Scholar
• Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research GroupEffect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction*1The Lancet19943438896499503
   Web of Science ®Google Scholar
• The Stroke Prevention in Atrial Fibrillation InvestigatorsBleeding during antithrombotic therapy in patients with atrial fibrillationArch Intern Med1564409416
   Google Scholar
• FihnSRisk factors for complications of chronic anticoagulation: a multicenter studyAnn Intern Med199311875115208280198
   PubMed Web of Science ®Google Scholar
• Stroke Prevention in Atrial Fibrillation InvestigatorsAdjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trialLancet199634890286336388782752
   PubMed Web of Science ®Google Scholar
• LinkinsL-AChoiPTDouketisJDClinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysisAnn Intern Med20031391189390014644891
   PubMed Web of Science ®Google Scholar
• GageBFLeskoLJPharmacogenetics of warfarin: regulatory, scientific, and clinical issuesJ Thromb Thrombolysis2008251455117906972
   PubMed Web of Science ®Google Scholar
• LoebsteinRDvoskinIHalkinHA coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistanceBlood200710962477248017110455
   PubMed Web of Science ®Google Scholar
• GageBFMilliganPBanetGDuncanJMcleodHMcleodHLUse of pharmacogenetics and clinical factors to predict the maintenance dose of warfarinThromb Haemost2004911879414691573
   PubMed Web of Science ®Google Scholar
• Coumadin® (warfarin) [package insert]Princeton, NJBristol-Myers Squibb20105
   Google Scholar
• WadeliusMChenLYErikssonNAssociation of warfarin dose with genes involved in its action and metabolismHum Genet20071211233417048007
   PubMed Web of Science ®Google Scholar
• MinersJOBirkettDJCytochrome P4502C9: an enzyme of major importance in human drug metabolismBr J Clin Pharmacol19984565255389663807
   PubMed Web of Science ®Google Scholar
• RendicSSummary of information on human CYP enzymes: human P450 metabolism dataDrug Metab Rev2002341-28344811996015
   PubMed Web of Science ®Google Scholar
• ZhouS-FZhouZ-WYangL-PCaiJ-PSubstrates, inducers, inhibitors and structure-activity relationships of human cytochrome P450 2C9 and implications in drug developmentCurr Med Chem200916273480367519515014
   PubMed Web of Science ®Google Scholar
• SimSCIngelman-SundbergMThe Human Cytochrome P450 (CYP) Allele Nomenclature website: a peer-reviewed database of CYP variants and their associated effectsHum Genomics20104427828120511141
   PubMedGoogle Scholar
• DelozierTLeeS-CCoulterSJGohBCGoldsteinJAFunctional characterization of novel allelic variants of CYP2C9 recently discovered in Southeast AsiansJ Pharmacol Exp Ther200531531085109016099926
   PubMed Web of Science ®Google Scholar
• WangDSunXGongYCYP2C9 promoter variable number tandem repeat polymorphism regulates mRNA expression in human liversDrug Metab Dispos201240588489122289258
   PubMed Web of Science ®Google Scholar
• LeschKPBallingUGrossJOrganization of the human serotonin transporter geneJ Neural Transm Gen Sect19949521571627865169
   PubMed Web of Science ®Google Scholar
• ContenteADittmerAKochMCRothJDobbelsteinMA polymorphic microsatellite that mediates induction of PIG3 by p53Nat Genet200230331532011919562
   PubMed Web of Science ®Google Scholar
• AlbanèseVBiguetNFKieferHBayardEMalletJMeloniRQuantitative effects on gene silencing by allelic variation at a tetranucleotide microsatelliteHum Mol Genet200110171785179211532988
   PubMed Web of Science ®Google Scholar
• BorrmannLSeebeckBRogallaPBullerdiekJHuman HMGA2 promoter is coregulated by a polymorphic dinucleotide (TC)-repeatOncogene200322575676012569368
   PubMed Web of Science ®Google Scholar
• AmadorMLOppenheimerDPereaSAn epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitorsCancer Res200464249139914315604284
   PubMed Web of Science ®Google Scholar
• DonningerHCashmoreTJScribaTFunctional analysis of novel SLC11A1 (NRAMP1) promoter variants in susceptibility to HIV-1J Med Genet2004414e4915060125
   PubMed Web of Science ®Google Scholar
• HeshmatiYMirabzadehAFeizzadeGA novel polymorphic purine complex at the 1.5 kb upstream region of the human caveolin-1 gene and risk of Alzheimer’s disease; extra-short alleles and accumulated allele homozygosityAm J Med Genet B Neuropsychiatr Genet2009150B224825318561140
   PubMed Web of Science ®Google Scholar
• Zarif YeganehMMirabzadehAKhorram KhorshidHRNovel extreme homozygote haplotypes at the human caveolin 1 gene upstream purine complex in sporadic Alzheimer’s diseaseAm J Med Genet B Neuropsychiatr Genet2010153B134734919475601
   PubMed Web of Science ®Google Scholar
• KleinTEAltmanRBErikssonNEstimation of the warfarin dose with clinical and pharmacogenetic dataN Engl J Med2009360875376419228618
   PubMed Web of Science ®Google Scholar
• HigashiMKVeenstraDLKondoLMAssociation between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapyJAMA2002287131690169811926893
   PubMed Web of Science ®Google Scholar
• SconceEAKhanTIWynneHAThe impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimenBlood200510672329233315947090
   PubMed Web of Science ®Google Scholar
• ShintaniMIeiriIInoueKGenetic polymorphisms and functional characterization of the 5’-flanking region of the human CYP2C9 gene: in vitro and in vivo studiesClin Pharmacol Ther200170217518211503012
   PubMed Web of Science ®Google Scholar
• TakahashiHIeiriIWilkinsonGR5’-flanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in white and Japanese patientsBlood200410383055305715070684
   PubMed Web of Science ®Google Scholar
• KramerMARettieAERiederMJCabacunganETHinesRNNovel CYP2C9 promoter variants and assessment of their impact on gene expressionMol Pharmacol20087361751176018310303
   PubMed Web of Science ®Google Scholar